Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands

Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands

The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the number and diversity of products in late-stage development will limit the commercial potential of individual brands simply due to saturation and price competition in each opioids market.

Scope

*This report gives a strategic analysis of the likely impact that recent events will have on the future opioids market

*Includes forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2018

*Provides a global opioids market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical markets

*Conclusions are supported by key opinion leader comment

Highlights

Purdue/Mundipharma/Napp Pharmaceutical's OxyContin (oxycodone controlled-release) is forecast to regain the prescriptions lost to generics following re-establishment of market exclusivity in the US. Sales peak at around $3 billion in 2009 across the seven major markets.

King Pharmaceutical's anti-abuse opioid franchise looks set to reach blockbuster levels over the forecast period. With combined sales of Remoxy (oxycodone controlled-release), Embeda (morphine extended-release and naltrexone) and the immediate-release opioid Acurox (oxycodone and niacin) forecast to generate around $1 billion per annum by 2018.

Reinvigoration of the short- and rapid-acting opioids market following approval of Fentora for non-cancer pain in the US, and the entry of regional specialist companies in the 5EU, will expand the market beyond that achieved by Cephalon to date.

Reasons to Purchase

*Quantify the current size of the global opioids market

*Assess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on opioid brand sales

*Understand the country-specific impact of key events in the opioids market during the forecast period 2009 to 2018

19-Mar-09 PDF & DataPack Pages: 133

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions